CRDF — Cardiff Oncology Inc
NASDAQ · Healthcare · Biotechnology
$1.02
-$0.01 (-0.97%)
Cardiff Oncology Inc (CRDF) is a biotechnology company listed on NASDAQ. It is led by Mark Erlander Ph.D., based in 11055 Flintkote Avenue, San Diego, CA, United States, 92121, with about 32 employees. Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest reported CRDF revenue for 2025-09-30 was $120.0K. Net income was -$11.3M. Revenue was down 0.8% from 2025-06-30 to 2025-09-30. CRDF currently screens at market cap $238.8M.
Use this CRDF page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CRDF quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CRDF SEC filings page. Lician reads the product cache first so this HTML stays unique to Cardiff Oncology Inc even when a live quote feed is slow.
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
CRDF Key Statistics
Market Cap
$238.83M
Volume
917,403
Previous Close
$1.00
Day Range
$0.98 – $1.06
EPS
-$0.95
Revenue
$683.00K
Net Income
-$45.43M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+40.0%
Profit Margin
-6651.7%
Employees
32
CRDF Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $683.00K | $488.00K | $386.00K | $359.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$45.43M | -$41.44M | -$38.70M | -$28.29M |
| EPS (Diluted) | -$0.95 | -$0.93 | -$0.89 | -$0.73 |
Total Assets
$97.19M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$51.47M
Operating Cash Flow
-$37.69M
Free Cash Flow
$0.00
Cardiff Oncology Inc Company Information
- CEO & Director
- Mark Erlander Ph.D.
- Headquarters
- 11055 Flintkote Avenue, San Diego, CA, United States, 92121
- Website
- www.cardiffoncology.com
- Phone
- 858 952 7570
- IPO / Founded
- 2004-07-27
- Sector
- Healthcare
- Industry
- Biotechnology